The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery.
As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.
Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.
The purpose of this study is to evaluate the use of a novel exercise treadmill test (ETT) electrocardiogram (ECG) indices as biomarkers in the assessment of Atherosclerotic Coronary Vascular Disease (ASCVD) (a Coronary Artery Disease or CAD) and to determine how the indices are affected by fatty
- History of stable coronary artery disease as defined by the presence of greater or equal to one of the following:
- Stable angina (chest pain) that is medically treated (minimum 3 month history)
- History of exercise treadmill test and/or other imaging suggesting ischemic coronary disease which has required ongoing medical treatment
- History of coronary angiography with or without coronary intervention/PTCA with greater or equal to 1 vessel with greater or equal to 50% stenosis at the end of the procedure (or after any intervention)
The purpose of this study is to identify the incidence, risk factors and biomarkers for subclinical chronic kidney damage kidney transplant patients recipients managed with early a steroid withdrawal protocol.
The primary objective of this trial is to assess the effectiveness, safety and clinical outcomes of the Thoraflex™ Hybrid Device in the treatment of aortic disease affecting the aortic arch and the descending thoracic aorta, with or without involvement of ascending aorta.
Main Study Group (All patients except Patients with Ruptured Aorta)
- Patients aged 18 years or over on date of consent
- Patient satisfies the inclusion criteria for one of the following categories:
A. Patient has acute dissection of the aorta
- Patient has acute aortic dissection and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires replacement, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta.
B. Patient has chronic dissection of the aorta
- Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta due to chronic dissection.
C. Patient has an aortic aneurysm (including connective tissue disorders)
- Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta.
Inclusion Criteria for Patients with Ruptured Aorta
- Patient has either a ruptured thoracic aorta, or, in the experience of the treating surgeon is at high risk of imminent rupture of the thoracic aorta.
Detailed eligibility criteria will be reviewed when you contact the study team.
This study is being done to collect blood samples from patients (men and women) diagnosed with liver disease, cirrhosis or liver or bile duct cancer.
- Men and women who are 18 years of age and older.
- Patients who have been diagnosed with liver disease, cirrhosis or liver or bile duct cancer.
- Detailed eligibility reviewed when the individual contacts the study team.
This clinical trial is for men and women newly diagnosed with glioblastoma or anaplastic gliomas. There is a great need for new treatment options for patients diagnosed with malignant brain tumors.
- Open to men and women who are 18 and older
- Diagnosed with glioblastoma or anaplastic glioma
- Participants must be newly diagnosed
- Detailed eligibility will be reviewed when you contact the study team
The purpose of this study is to determine whether etrolizumab is a safe and effective treatment for patients with moderate to severe Crohn’s Disease.
- 18-80 years of age (inclusive)
- Moderately to severely active Crohn's disease as determined by the Crohn's Disease
- Activity Index (CDAI), patient reported outcomes and endoscopically defined disease activity in the ileum and/or colon
- Intolerance, loss of response or failure to respond to corticosteroids (CS) or, immunosuppressants (IS), or TNF inhibitors within the previous 5 years
- Use of effective contraception as defined by the protocol
- A history of, or current conditions affecting the digestive tract, such as ulcerative colitis, indeterminant colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome
- Planned surgery for CD Ileostomy or colostomy
- Has received non-permitted inflammatory bowel disease (IBD) therapies (including natalizumab, vedolizumab, and efilizumab, as stated in the protocol)
- Chronic hepatitis B or C infection, HIV, active or latent tuberculosis (patients with prior history of BCG vaccination must pass protocol-defined screening criteria)